Further analysis of the latest research found that serum IL-37 in AML patients were negatively correlated with IL-6, and rhIL-37 inhibited the expression of LPS-stimulated IL-6 in AML patients PBMCs (133), suggesting that IL-37 is involved in AML through the IL-6 signaling pathway, and may become a considerable innovative strategy for its treatment and prognosis. Here, IL37 is linked to acute myeloid leukemia.